Researchers Develop Anti-tumor Compounds
The structure of the obtained substance is 3,4-diaryl-5-carboxy-4,5-dihydroisoxazole-2-oxide. Credit: Victor Khrustalev
Employees of RUDN University are actively involved in the development of chemical compounds isoxazoles, capable of suppressing the growth of malignant tumors. The results of the study were published in Tetrahedron.
Biological activity spectrum of isoxazoles is quite wide: they exhibit antiviral, anti-inflammatory and antitumor activity. Compounds containing the isoxazole ring are effective in treating cancer. In particular, one of them is known to effectively slow down the growth of cancer cells and polymerization of the tubulin protein, thus contributing to the decline of the inflammatory process. Another one reduces the activity of the protein Hsp90 (one of the heat shock proteins), which helps proteins in cancer cells to properly fold into structures and protects them from heat shock.
However, the development of isoxazole derivatives is extremely complex: the necessary catalysts and reagents are not available on an industrial scale, and the synthesis of this class of substances is ineffective and poorly regulated. Therefore, the goal of the authors was to create an efficient and inexpensive method of regioselective (with a certain predetermined arrangement of the functional substituents regarding the heteroatoms in the isoxazole ring) synthesis of isoxazoles from available materials under mild conditions that do not require high temperatures and other factors that may complicate the synthesis.
During the work, the scientists synthesized 3,4-diaryl-5-carboxy-4,5-dihydroisoxazole-2-oxides. These compounds include a central five-membered heterocycle, containing heteroatoms of nitrogen and oxygen, that occupy neighboring positions. There are also substituents at carbon atoms-various functional groups whose position concerning heteroatoms can be changed.
"The article develops biologically active compounds that exhibit antitumor activity. Employees of RUDN University had been studying the structure, geometry and interrelation between structure and properties.We found that with different arrangement of substituents in the cycle, the properties of the compound also change", as Victor Khrustalev, DSc in Physical Chemistry, Chair of Inorganic Chemistry Department of RUDN University said.
"The compounds possess a potential anti-cancer and antiviral activity, which, undoubtedly, must be carefully studied. In order to understand whether the compound is effective, it is necessary to carry out biological testing on living organisms. However, at first we should undertake a detailed study of how the manifested properties of the resulting compounds depend on the position of the substituents in the isoxazole cycle, that is, how the biological properties of the substance being developed depend on its structure", the scientist concluded.
The work was carried out in cooperation with scientists from N.D. Zelinsky Institute Of Organic Chemistry Russian Academy Of Sciences and Koltzov Institute of Developmental Biology of Russian Academy of Sciences.
This article has been republished from materials provided by RUDN University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Chernysheva, N. B., Maksimenko, A. S., Andreyanov, F. A., Kislyi, V. P., Strelenko, Y. A., Khrustalev, V. N., . . . Semenov, V. V. (2017). Synthesis of 3,4-diaryl-5-carboxy-4,5-dihydroisoxazole 2-oxides as valuable synthons for anticancer molecules. Tetrahedron. doi:10.1016/j.tet.2017.10.016
Antibody Drug-Conjugate to Target Treatment-Resistant Childhood LeukemiaNews
Researchers have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment.
Infants Should Interact with Other Children to Reduce Leukemia RiskNews
A major new analysis reveals for the first time the likely cause of most cases of childhood leukaemia, following more than a century of controversy about its origins. Research concludes that the disease is caused through a two-step process of genetic mutation and exposure to infection that means it may be preventable with treatments to stimulate or 'prime' the immune system in infancy.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018